ArticleTherapeutics and clinical risk management2013

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.

Karl-Erik AnderssonPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.